Literature DB >> 8437830

Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment.

C L Shields1, J A Shields, P De Potter, S Minelli, C Hernandez, L W Brady, J R Cater.   

Abstract

BACKGROUND: Radioactive episcleral plaque brachytherapy is a treatment method for selected retinoblastomas. The authors have used this technique since 1976 as both a primary and a secondary treatment method after other methods failed to achieve tumor control.
METHODS: A review of the records of 400 consecutive children with retinoblastoma showed that solitary plaque radiotherapy was used as a method of management in 103 cases. The authors' overall experience was evaluated, and the results between primary and secondary plaque therapies were compared in these 103 cases.
RESULTS: Of the 103 tumors, the mean basal diameter was 7 mm, and the mean thickness was 4 mm. Overlying vitreous seeds were clinically apparent in 50 cases (48%). The mean proximity of the tumor margin to the optic disc margin was 6 mm and to the foveola was 6 mm. The mean follow-up period was 40 months. In 89 cases (86%), the tumor was controlled by one plaque application, whereas in 13 cases (13%), tumor recurrence after initial tumor shrinkage necessitated subsequent treatment. Final visual outcome was good in 63 cases (62%), poor in 30 (29%), enucleation in 9 (9%), and unknown in 1 case. The poor vision was due to foveal retinoblastoma (with or without amblyopia) in 25 cases (83%). Eight of the nine enucleated eyes were treated initially with external beam radiotherapy then later with plaque radiotherapy. In 31 cases (30%), plaque radiotherapy was used as a primary treatment to the tumor, while in 72 cases (70%), it was a secondary form of management after failure of other methods to control the tumor. Statistical analysis showed that tumors treated with plaque radiotherapy as a primary measure were more likely to be larger in in base (P = 0.01) and thickness (P = 0.01) than secondary treated tumors. The secondary treated retinoblastomas were more likely to have vitreous seeds (P = 0.02) than the primary treated tumors. The rate of tumor control and patient survival was similar between the two groups.
CONCLUSION: Plaque radiotherapy is very effective in treating selected retinoblastomas with a high rate of tumor control and patient survival. It can be used successfully as a primary or a secondary treatment for tumors that have not been adequately controlled by other therapeutic methods.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437830     DOI: 10.1016/s0161-6420(93)31667-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Pathological findings in enucleated eyes after intravitreal melphalan injection.

Authors:  Fariba Ghassemi; Fahimeh Asadi Amoli
Journal:  Int Ophthalmol       Date:  2013-09-17       Impact factor: 2.031

3.  Intravitreal chemotherapy for recurrent retinoblastoma in an only eye.

Authors:  S Seregard; E Kock; E af Trampe
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

4.  Thermochemotherapy in hereditary retinoblastoma.

Authors:  A O Schueler; C Jurklies; H Heimann; R Wieland; W Havers; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

5.  A biological tissue adhesive and dissolvent system for intraocular tumor plaque radiotherapy: an in vivo animal model experiment.

Authors:  Ofira Zloto; Dror Alezra; Oded Sagiv; Michael Belkin; Vicktoria Vishnevskia Dai; Iris Moroz; Gahl Greenberg; Elad Ben-Artsi; Ido Didi Fabian
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-27       Impact factor: 3.117

6.  High resolution magnetic resonance imaging of retinoblastoma.

Authors:  A O Schueler; N Hosten; N E Bechrakis; A J Lemke; P Foerster; R Felix; M H Foerster; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

Review 7.  Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Authors:  Eleanor M Pritchard; Michael A Dyer; R Kiplin Guy
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 8.  The pathology of ocular cancer.

Authors:  R C Eagle
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

9.  Radiation Retinopathy 47 Years following Brachytherapy for Retinoblastoma.

Authors:  Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-11-03

10.  Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma.

Authors:  John T Lucas; Rose McGee; Catherine A Billups; Ibrahim Qaddoumi; Thomas E Merchant; Rachel C Brennan; Jiangrong Wu; Matthew W Wilson
Journal:  Br J Ophthalmol       Date:  2018-06-28       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.